Navigation Links
Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
Date:3/6/2008

KIRKLAND, Wash., March 6 /PRNewswire/ -- Pathway Medical Technologies, which is developing innovative medical devices for the treatment of arterial disease, announced that Paul Buckman has been named as the new Chairman of the Board of Directors. He replaces Dan Galles, who has been acting Board Chairman since late 2006.

"We are very pleased Paul has accepted the role of Chairman. He brings an extensive range of industry experience to the Pathway board, including early commercialization experience. This is especially important to the company as it prepares for the launch of its first product, the Pathway PV(TM) Artherectomy System," said Galles.

"Since Paul joined our Board in 2007, he has become a real asset. His deep commercial experience with a variety of companies has already proven useful," said Tom Clement, Pathway President and CEO, "and I expect in his new role, Paul's vision and leadership will continue to benefit both the company and the patients who will be treated with our device."

Buckman, who has worked in the medical device industry for over 30 years, is currently CEO and a director of Devax, Inc., a development-stage cardiovascular device company. He joined Devax in 2006 from St. Jude Medical, Inc. where he was an executive officer and President of its Cardiology Division. Before St. Jude Medical, Buckman served as Chairman of the Board of Directors and CEO of ev3, LLC, which he co-founded. Earlier in his career he was with Boston Scientific Corporation, where he held several executive positions before being named President of the Scimed Division, a post he held for 10 years. In the course of his career, Buckman has served on the Board of a variety of companies, including: EndiCor, Inc., Microvena, Inc., Micro Therapeutics, Inc., and Velocimed, Inc., which he also co-founded.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to design, market and manufacture medical devic
'/>"/>

SOURCE Pathway Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Genetic pathway critical to disease, aging found
2. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
3. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
4. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
9. LifeNet Health(R) Unveils New Biomedical Spine Implant
10. IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology
11. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ntries have an opportunity to take the lead in two... University of Valencia (UV), working together wit...ive fabric of the Spanish biotechnology industry. ...ctors have more clout than those in English-speaki... and plants has been overlooked by the leading cou...
(Date:11/20/2009)...PRNewswire-FirstCall/ -- Dendreon Corporation (Nas...d Drug Administration (FDA) provided written ackno...cense Application (BLA) for PROVENGE® (sipule...ned a Prescription Drug User Fee Act (PDUFA) date ...endreon,s amended BLA. Dendreon is seeking licens...
(Date:11/20/2009)...November 20 Karolinska Development...und (EIF) has entered into a,co-investment agreeme...e,managed by Karolinska Development and used to in...rmaceutical and medical technology companies. EIF,...ment fund. The agreement,represents EIF,s largest ...
(Date:11/20/2009)...LER TOLEDO recently announced that a free webinar,...ing At-Line Particle Characterization”, will...r, the application of in situ particle characteriz...optimize a series of roller compaction runs while ...action forces. , (PRWEB) ...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2
...RNewswire-FirstCall/ - Victhom Human Bionics Inc.,...urobionix division has achieved ISO 13485:2003 cer...This certification, an internationally recognized ...ational Organization for Standardization (ISO), co...bionix division had received back in August 2008 f...
...n. 23 Novavax, Inc. (Nasdaq: NVAX ) a clinical-...nny Heaton, V.P., and Chief Medical Officer, will ...hington 2009 conference on January 26, 2009 at the...ticipating in the Focus Session ,What benefits are...anufacturing solutions providing in practice, and ...
...Jan. 23 Cordex Pharma, Inc., formerly known as Du... announced today that it will host a scientific br.... EST in New York City. , , The keynote speaker ...Geller Professor for Research in Cardiovascular Di...stry at Duke University Medical Center in Durham...
Other Biology Technology:Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5
(Date:11/22/2009)... South Korean scientists have succeeded in produci... bioengineering, rather than through the use of fo...earch, which may now allow for the production of e... two papers in the journal Biotechnology and Bioe.... , Polymers are molecules found in everyday li...
(Date:11/22/2009)... gene deletion can increase the likelihood of immu...tion, an international team of researchers reports...e Genetics . When the gene, called UGT2B17, is mis...cipient,s, transplants have a significantly greate...sus-host disease, in which immune cells from the d...
(Date:11/22/2009)...ember 23, 2009 Agios Pharmaceuticals today announ...first time, that the mutated IDH1 gene has a novel...gene, or oncogene. This breakthrough discovery sho...lite, 2-hydroxyglutarate (2HG), which may contribu...liomas, the most common type of brain cancers. Thi...
Breaking Biology News(10 mins):Bioengineers succeed in producing plastic without the use of fossil fuels 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4US Farms Inc Aloe Vera Products Now Available on eBay 59223 1US Farms Inc Aloe Vera Products Now Available on eBay 59223 2US Farms Inc Aloe Vera Products Now Available on eBay 59223 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Rest Assured With Clinically Tested Anti Snore Pillow 59219 1Rest Assured With Clinically Tested Anti Snore Pillow 59219 2
... think of the skull as packaging for the brain and...but a team of researchers now thinks that developm...rovertibly linked. , The researchers, including b...er scientist, looked at the CT scans and MRIs of i...a condition where one or more of the sutures -- fi...
...a year, researchers watched patiently as a few com...to more than 15,000 slightly different shapes. In ...f a second. In the end, however, this suspended an...otential new drug target to fight drug-resistant A...entists made the discovery while studying how one ...
...rgia researchers have developed an anti-microbial ...oxic. , Already, the treatment has helped heal Sp...y case, and Gasper, a beluga whale at the Georgia ...a human application for the technology, which they...hie, a distinguished research scientist in the dep...
Other Biology News:Relationship of brain and skull more than just packaging 2Relationship of brain and skull more than just packaging 3Major WHO study concludes calcium supplements can reduce complications during pregnancy 2Major WHO study concludes calcium supplements can reduce complications during pregnancy 3Major WHO study concludes calcium supplements can reduce complications during pregnancy 4Major WHO study concludes calcium supplements can reduce complications during pregnancy 5New antimicrobial compound adheres to skin to promote healing 2
ApoStat Intracellular Caspase Detection (FITC-VD-FMK) from R&D Systems
Mouse Anti-Rat RT1Bu (Class II Polymorphic) Monoclonal Antibody, Biotin Conjugated from AbD Serotec
Mouse Anti-Guinea Pig T-Cells, Pan Monoclonal Antibody, FITC Conjugated from AbD Serotec
Mouse Anti-Rabbit T LYMPHOCYTES Monoclonal Antibody, Unconjugated, Clone KEN-5 from AbD Serotec
Biology Products: